Home › Research › Vascular contributions
Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors
Chi‐Hung Liu, Ming‐Lung Tsai, Ning‐I Yang, Ting-Yu Chang, Tien‐Hsing Chen, Yi‐Chia Wei. Alzheimer s & Dementia, 2026-02-01
Topic: Risk, prevention and care in population studies
Plain-language summary
The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94). The telmisartan group also had a lower risk of all strokes when compared to NT-ARB (HR: 0.78; 95% CI: 0.61 to 0.99) in the time-dependent cohort. Use of telmisartan may be associated with marginally lower risks of all dementias and strokes compared to other RAS inhibitors in patients with HTN. HIGHLIGHTS: Whether telmisartan is associated with a reduced risk of dementia compared to other RAS inhibitors in patients with HTN and varying blood sugar levels remains unclear. Our cohort study aimed to investigate the long-term cognitive and cerebrovascular outcomes of hypertensive patients receiving telmisartan compared to those receiving other RAS inhibitors. Eligible individuals were categorized into three groups. Use of telmisartan may be associated with marginally lower risks of all dementia and stroke compared with other RAS inhibitors in patients with HTN.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 39,665 participants. Among people with hypertension, those taking telmisartan had marginally lower risks of all dementias and strokes than those taking other renin-angiotensin system inhibitors. Reported effect size: HR: 0.67; HR: 0.78.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, C., Tsai, M., Yang, N., Chang, T.-Y., Chen, T., & Wei, Y. (2026). Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors. Alzheimer s & Dementia. https://doi.org/10.1002/alz.71153
Vancouver
Liu C, Tsai M, Yang N, Chang T.-Y, Chen T, Wei Y. Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors. Alzheimer s & Dementia. 2026. doi:10.1002/alz.71153. PMID: 41686713.
BibTeX
@article{liu2026-41686713,
author = {Liu, Chi‐Hung and Tsai, Ming‐Lung and Yang, Ning‐I and Chang, Ting-Yu and Chen, Tien‐Hsing and Wei, Yi‐Chia},
title = {{Risks of dementia and stroke in patients with hypertension using telmisartan or other renin‑angiotensin system inhibitors}},
journal = {Alzheimer s \& Dementia},
year = {2026},
doi = {10.1002/alz.71153},
pmid = {41686713},
url = {https://doi.org/10.1002/alz.71153}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The telmisartan group had the lowest risk of all dementias (telmisartan vs NT-ARB: hazard ratio [HR]: 0.78; 95% confidence interval [CI]: 0.60 to 1.01; telmisartan vs angiotensin-converting enzyme inhibitor: HR: 0.67; 95% CI: 0.48 to 0.94).
- The telmisartan group also had a lower risk of all strokes when compared to NT-ARB (HR: 0.78; 95% CI: 0.61 to 0.99) in the time-dependent cohort.
- Use of telmisartan may be associated with marginally lower risks of all dementias and strokes compared to other RAS inhibitors in patients with HTN.
- HIGHLIGHTS: Whether telmisartan is associated with a reduced risk of dementia compared to other RAS inhibitors in patients with HTN and varying blood sugar levels remains unclear.
- Our cohort study aimed to investigate the long-term cognitive and cerebrovascular outcomes of hypertensive patients receiving telmisartan compared to those receiving other RAS inhibitors.
Why it matters
Among people with hypertension, those taking telmisartan had marginally lower risks of all dementias and strokes than those taking other renin-angiotensin system inhibitors. The authors describe this as a possible association rather than a proven protective effect.
Study details
- Study designcohort study
- Participants39,665
- Effect sizeHR: 0.67; HR: 0.78
- Evidence strengthModerate
How this study scored 59/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 39,665 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 14.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Yi‐Chia Wei: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | National Taiwan University: institution h-index 752 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41686713) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Vascular contributions from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.